ciglitazone has been researched along with Breast Neoplasms in 13 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The obesity hormone leptin has been implicated in breast cancer development." | 7.79 | Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. ( Amodeo, V; Bazan, V; Caruso, S; Cicero, G; Contaldo, C; Corsini, LR; Fanale, D; Fiorio, E; Insalaco, L; Lo Re, G; Mercanti, A; Russo, A; Surmacz, E; Terrasi, M, 2013) |
| "In light of the clinical relevance of targeting cyclin D1 in breast cancer, we have investigated the mechanism underlying the effect of the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and ciglitazone on cyclin D1 repression." | 7.73 | Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. ( Brueggemeier, RW; Chen, CS; Chen, KF; Huang, JW; Kulp, SK; Shapiro, CL; Shiau, CW; Yang, YT, 2005) |
| "Thus, PPARgamma-induced inhibition of breast cancer cell growth is due, in part, to proteasome-dependent degradation of cyclin D1 (and ER alpha), and this pathway may be important for other cancer cell lines." | 5.32 | Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. ( Burghardt, R; Qin, C; Safe, S; Smith, R; Stewart, J; Wormke, M, 2003) |
| "The obesity hormone leptin has been implicated in breast cancer development." | 3.79 | Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. ( Amodeo, V; Bazan, V; Caruso, S; Cicero, G; Contaldo, C; Corsini, LR; Fanale, D; Fiorio, E; Insalaco, L; Lo Re, G; Mercanti, A; Russo, A; Surmacz, E; Terrasi, M, 2013) |
| "In light of the clinical relevance of targeting cyclin D1 in breast cancer, we have investigated the mechanism underlying the effect of the peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists troglitazone and ciglitazone on cyclin D1 repression." | 3.73 | Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. ( Brueggemeier, RW; Chen, CS; Chen, KF; Huang, JW; Kulp, SK; Shapiro, CL; Shiau, CW; Yang, YT, 2005) |
| "The PPAR-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J(2) and ciglitazone, and the PPAR-alpha ligand, WY-14643, were examined for their effects on proliferation and apoptosis of A375 melanoma, DU145 and PC3 prostate cancer, and MB-MDA-231 breast cancer." | 3.73 | PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. ( Liu, H; Meadows, GG; Núñez, NP, 2006) |
| "Doxorubicin is effective against breast cancer, but its major side effect is cardiotoxicity." | 1.39 | Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms. ( Arif, IS; Boateng, SY; Greco, F; Hooper, CL; Williams, AC, 2013) |
| "We used the common model of human breast cancer MCF-7 and examined the ability of MEHP and MBP to activate human PPARs in this system." | 1.33 | Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. ( Cabot, PJ; Davis, B; Monteith, GR; Roberts-Thomson, SJ; Robinson, JA; Venkata, NG, 2006) |
| "Thus, PPARgamma-induced inhibition of breast cancer cell growth is due, in part, to proteasome-dependent degradation of cyclin D1 (and ER alpha), and this pathway may be important for other cancer cell lines." | 1.32 | Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. ( Burghardt, R; Qin, C; Safe, S; Smith, R; Stewart, J; Wormke, M, 2003) |
| "Treatment of MDA-MB-231 breast cancer cells with NS-398 (a COX-2 inhibitor) or ciglitazone (CGZ, a PPARgamma-ligand) significantly inhibited cell proliferation and markedly increased apoptotic rates." | 1.32 | Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells. ( Badawi, AF; Badr, MZ; Michael, MS, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mora, FD | 1 |
| Jones, DK | 1 |
| Desai, PV | 1 |
| Patny, A | 1 |
| Avery, MA | 1 |
| Feller, DR | 1 |
| Smillie, T | 1 |
| Zhou, YD | 1 |
| Nagle, DG | 1 |
| Arif, IS | 1 |
| Hooper, CL | 1 |
| Greco, F | 1 |
| Williams, AC | 1 |
| Boateng, SY | 1 |
| Davies, GF | 1 |
| Ross, AR | 1 |
| Arnason, TG | 1 |
| Juurlink, BH | 1 |
| Harkness, TA | 1 |
| Terrasi, M | 1 |
| Bazan, V | 1 |
| Caruso, S | 1 |
| Insalaco, L | 1 |
| Amodeo, V | 1 |
| Fanale, D | 1 |
| Corsini, LR | 1 |
| Contaldo, C | 1 |
| Mercanti, A | 1 |
| Fiorio, E | 1 |
| Lo Re, G | 1 |
| Cicero, G | 1 |
| Surmacz, E | 1 |
| Russo, A | 1 |
| Qin, C | 1 |
| Burghardt, R | 1 |
| Smith, R | 1 |
| Wormke, M | 1 |
| Stewart, J | 1 |
| Safe, S | 1 |
| Michael, MS | 1 |
| Badr, MZ | 1 |
| Badawi, AF | 1 |
| Burgermeister, E | 1 |
| Tencer, L | 1 |
| Liscovitch, M | 1 |
| James, SY | 1 |
| Lin, F | 1 |
| Kolluri, SK | 1 |
| Dawson, MI | 1 |
| Zhang, XK | 1 |
| Huang, JW | 1 |
| Shiau, CW | 1 |
| Yang, YT | 1 |
| Kulp, SK | 1 |
| Chen, KF | 1 |
| Brueggemeier, RW | 1 |
| Shapiro, CL | 1 |
| Chen, CS | 1 |
| Allred, CD | 1 |
| Kilgore, MW | 1 |
| Núñez, NP | 1 |
| Liu, H | 1 |
| Meadows, GG | 1 |
| Venkata, NG | 1 |
| Robinson, JA | 1 |
| Cabot, PJ | 1 |
| Davis, B | 1 |
| Monteith, GR | 1 |
| Roberts-Thomson, SJ | 1 |
| Yee, LD | 1 |
| Sabourin, CL | 1 |
| Liu, L | 1 |
| Li, HM | 1 |
| Smith, PJ | 1 |
| Seewaldt, V | 1 |
| Kniss, DA | 1 |
13 other studies available for ciglitazone and Breast Neoplasms
| Article | Year |
|---|---|
Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Disulfides; Dose-Response Relationship, Drug; Female; Histone | 2006 |
Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms.
Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cells, Culture | 2013 |
Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Topics: Acetylation; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Butyrates; Cell Line, Tumor | 2010 |
Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.
Topics: Benzophenones; Binding Sites; Breast Neoplasms; Cell Movement; Cell Survival; Dose-Response Relation | 2013 |
Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cyclin D1; Cysteine Endopeptidases; Down-Regulation; Estrogen Recep | 2003 |
Inhibition of cyclooxygenase-2 and activation of peroxisome proliferator-activated receptor-gamma synergistically induces apoptosis and inhibits growth of human breast cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspases; Cell Cycle; Cell Divis | 2003 |
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells.
Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveoli | 2003 |
Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
Topics: Apoptosis; Benzoates; Breast Neoplasms; Cell Division; Female; Gene Expression Regulation, Neoplasti | 2003 |
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromans; Cyclin D1; Down-Regulation; Female; Humans; PPAR gamma | 2005 |
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines.
Topics: Alitretinoin; Anilides; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Female; | 2005 |
PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells.
Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferatio | 2006 |
Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast.
Topics: Breast Neoplasms; Butyrates; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Diethylhexy | 2006 |
Peroxisome proliferator-activated receptor gamma activation in human breast cancer.
Topics: Breast Neoplasms; Cell Division; DNA-Binding Proteins; Female; Genes, Reporter; Humans; Hypoglycemic | 1999 |